Search

Some live vaccines, particularly Bacillus Calmette‐Guérin (BCG), oral polio vaccine (OPV), and measles vaccine, can reduce the incidence of all‐cause mortality by outreaching the mere control of specific infections and exerting off‐target effects. Asides from the prevention of viral infection, some other vaccines, such as those against flu or rotavirus, could reduce the risk of developing autoimmunity. The nonspecific effects of vaccines are mediated by the innate immune system, mainly through the so‐called trained innate immunity. These observations paved the way for developing tolerogenic and trained immunity‐based vaccines with substantial implications for more effective use of vaccines and combat vaccine hesitancy. [ABSTRACT FROM AUTHOR]

Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live‐attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a "universal vaccine" strategy. [ABSTRACT FROM AUTHOR]